Continue Reading
Full article on Bloomberg
How Ketamine Spawned a $1.7 Billion J&J Blockbuster Drug
Market Intelligence Analysis
AI-Powered
Why This Matters
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Sentiment
Neutral
AI Confidence
94%
Time Horizon
Short Term
Article Context
Note: This is a brief excerpt for context. Click below to read the full article on the original source.
Spravato, the ketamine-derived nasal spray from Johnson & Johnson, was once seen as a long shot. It was difficult to deliver, heavily regulated and slow to catch on. Find out how it became a billion-dollar drug and part of a new model for treating depression. (Source: Bloomberg)
AI Breakdown
Summary
FinBERT analysis of financial text showing neutral sentiment with 94.1% confidence.
Time Horizon
Short Term
Original article published by
Bloomberg
on April 30, 2026.
Analysis and insights provided by AnalystMarkets AI.
Analysis and insights provided by AnalystMarkets AI.